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Background: Mucin-1 is known to be over-expressed by various human carcinomas and is shed into the circulation
where it can be detected in patient’s serum by specific anti-Mucin-1 antibodies, such as the tumour marker assays
CA 15–3 and CA 27.29. The prognostic value of Mucin-1 expression in ovarian carcinoma remains uncertain. One
aim of this study was to compare the concentrations of Mucin-1 in a cohort of patients with either benign or
malignant ovarian tumours detected by CA 15–3 and CA 27.29. Another aim of this study was to evaluate Mucin-1
expression by immunohistochemistry in a different cohort of ovarian carcinoma patients with respect to grade,
stage and survival.
Methods: Patients diagnosed with and treated for ovarian tumours were included in the study. Patient
characteristics, histology including histological subtype, tumour stage, grading and follow-up data were available
from patient records. Serum Mucin-1 concentrations were measured with ELISA technology detecting CA 15–3 and
CA 27.29, Mucin-1 tissue expression was determined by immunohistochemistry using the VU4H5 and VU3C6
anti-Mucin-1 antibodies. Statistical analysis was performed by using SPSS 18.0.
Results: Serum samples of 118 patients with ovarian tumours were obtained to determine levels of Mucin-1.
Median CA 15–3 and CA 27.29 concentrations were significantly higher in patients with malignant disease
(p< 0.001) than in patients with benign disease.
Paraffin-embedded tissue of 154 patients with ovarian carcinoma was available to determine Mucin-1 expression.
The majority of patients presented with advanced stage disease at primary diagnosis. Median follow-up time was
11.39 years. Immunohistochemistry results for VU4H5 showed significant differences with respect to tumour grade,
FIGO stage and overall survival. Patients with negative expression had a mean overall survival of 9.33 years
compared to 6.27 years for patients with positive Mucin-1 expression.
Conclusions: This study found significantly elevated Mucin-1 serum concentrations in ovarian carcinoma patients
as compared to those women suffering from benign ovarian diseases. However, it needs to be noted that Mucin-1
concentrations in carcinoma patients showed a rather high variability. Results from immunohistochemistry indicate
that Mucin-1 has a prognostic relevance in ovarian carcinomas when evaluating the expression by VU4H5 antibody.
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Ovarian cancer is one of the most lethal malignancies.
Patients with early stage ovarian cancer are often asymp-
tomatic or report nonspecific symptoms so ovarian can-
cer is mostly diagnosed at an advanced stage [1,2].
Primary treatment includes operative cytoreduction
and subsequent combined platinum-based chemothe-
rapy. Though reported primary response rates are around
80%, ovarian cancer is the most lethal gynecological ma-
lignancy since 60-70% of the patients relapse or die within
5 years after primary diagnosis [1,3,4]. The prognosis of
the disease could be improved by early detection, but this
is difficult to achieve.
Mucin-1 (MUC1) is a heterodimeric protein complex
that is normally located at the apical border of secretory
epithelial cells. The N-terminal subunit is the mucin com-
ponent of the protein consisting of variable numbers of
tandem repeats that are linked with glycans. It is con-
nected to the cell surface by association with the trans-
membrane C-terminal subunit. The physiological function
of the protein is to build a barrier against toxins, microor-
ganisms and other forms of stress [5]. During cell trans-
formation and loss of polarity the protein expression is
up-regulated. MUC1 is known to be over-expressed by
various human carcinomas and is shed into the circulation
where different epitopes can be detected in the serum of
patients by specific anti-MUC1 antibodies [4,6,7]. CA
15–3 and CA 27.29 are available tumour marker assays
for detecting MUC1. Monoclonal antibodies which are
specific for the different tandem repeat units in the pro-
tein core of the MUC1 antigen are used in these kits and
automated analysers produce results that are reliable [8].
Both markers are structurally similar and CA 15–3 is rou-
tinely utilised as a diagnostic and prognostic marker in
breast cancer [9,10]. Clinical correlation studies compa-
ring CA 15–3 levels and CA 27.29 levels in breast cancer
patients typically show high correlation coefficients, sug-
gesting that CA 27.29 would be suitable for routine use
[11,12]. Recently published data confirmed this assump-
tion [13], but the diagnostic relevance for patients with
ovarian tumours of uncertain dignity remains unclear.
The Expression of MUC1 by immunohistochemistry
(IHC) can also be detected by monoclonal antibodies. A
large panel of epitopes exists to evaluate the prognostic
value of MUC1 expression. VU4H5 and VU3C6 are both
anti-MUC1 antibodies of the same isotype (mouse IgG1)
and are directed at the core protein of MUC1. The anti-
body VU4H5 was generated with a synthetic MUC1
peptide consisting of three tandem repeats as immuno-
gen. Both antibodies, VU3C6 and VU4H5, were eva-
luated during the ISOBM TD-4 International Workshop
on Monoclonal Antibodies against MUC1. They were
confirmed in their MUC1 specificity. A major difference
between the two antibodies is their epitope sequence.For VU3C6 the epitope sequence is GVTSAPDTRPAP
and for VU4H5 it is APDTRPAP [14].
Overexpression of MUC1 has been reported in ovarian
cancer, but the information is limited due to small num-
bers and the correlation between overexpression and
prognosis remains unclear [15-17].
One aim of this study was to compare the concentra-
tions of MUC1 in a cohort of patients with either benign
or malignant ovarian tumours detected by CA 15–3 and
CA 27.29. Another aim was to evaluate the MUC1 ex-
pression by IHC in a different cohort of ovarian carci-
noma patients with respect to grade, stage and survival.
Methods
Patients
Patients from our study whose sera were tested for CA
15–3 and CA 27.29 underwent surgery at the Department
of Obstetrics and Gynecology, Campus Innenstadt, LMU
Munich between 2002 and 2006. Blood samples were
obtained prior to surgery and were assigned to either the
group of patients with benign (n=74) or malignant (n=44)
disease of the ovary after histopathological examination.
Histological evaluation and staging of tumour tissue was
performed by an experienced gynaecological pathologist
(D.M.) according to the criteria of the International Fede-
ration of Gynaecologists and Obstetricians (FIGO) and
the World Health Organization (WHO).
Patients whose tissue was examined by IHC for MUC1
expression retrospectively had undergone surgery for
primary ovarian carcinoma at the Department of Obste-
trics and Gynecology, Campus Innenstadt, LMU Munich
between 1990 and 2002. Patients with ovarian borderline
tumours were excluded from the study. Again, histo-
logical evaluation and staging was performed by an
experienced gynaecological pathologist. Clinical data was
abstracted from patient charts and the tumour registry
database. MUC1 expression was evaluated in terms of a
possible correlation with tumour stage, grade and sur-
vival. The extent of the primary tumour (pT) is defined
according to the UICC: pT1= the tumour is limited to
the ovaries, pT2= the tumour has spread to the pelvis,
pT3= the tumour has spread beyond the pelvis and/or
to regional lymphnodes.
Sample description
Tumour samples of 154 primary ovarian carcinoma
patients were evaluated by IHC for MUC1. Median age
at primary diagnosis was 58.8 years (range 18–88). The
majority of patients presented with advanced stage dis-
ease at time of primary diagnosis [FIGO I: n=34 (22.1%),
FIGO II: n=10 (6.5%), FIGO III: n=102 (66.2%), FIGO
IV: n=3 (1.9%), missing: n=5 (3.2%)]. See Table 1 for
detailed patient characteristics. Median follow-up time
was 11.39 years. 26 patients relapsed and 91 died.
Table 1 Patient characteristics of ovarian carcinoma
patients whose tissue samples were stained by
immunohistochemistry for MUC1 expression
Ovarian carcinoma patients (n) 154
Age at primary diagnosis (a) 58.8 (range 18–88)
Histology (%) serous 70.8
mucinous 8.4
endometrioid 13.6
clear cell 7.1
Tumor grade (%) low grade 24.7
intermediate 33.1
high grade 34.4
missing 7.8
Tumor stage (FIGO) (%) I 22.1
II 6.5
III 66.2
IV 1.9
missing 3.2
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The study was approved by the local ethics committee
of the Ludwig-Maximilians University Munich and was
carried out in compliance with the guidelines of the Hel-
sinki Declaration of 1975 (approval with the reference
number 138/03). The study participants gave their writ-
ten consent and samples and clinical information were
used anonymously.
Enzyme-linked-immunosorbent-assay (ELISA)
As previously described [13,18].
Immunohistochemistry
IHC for MUC1 was performed as described elsewhere
[19]. Antibodies used for staining were the anti-VU4H5
(mouse IgG; Zymed, Berlin, Germany) and anti-VU3C6
(1 mg/ml, mouse IgG; Serotec, Munich, Germany).
VU4H5
In short, paraffin-fixed tissue sections were dewaxed
with xylol for 15 minutes and placed into 100% ethanol.
Blocking of the endogenous peroxidase was done by a
combination of hydrogen peroxide and methanol for 20
minutes. Next, slides were dehydrated in descending
concentrations of ethanol and then exposed for epitope
retrieval for 10 minutes in a pressure cooker using so-
dium citrate buffer (pH 6.0) containing 0.1 M citric acid
and 0.1 M sodium citrate in distilled water. After cool-
ing, slides were washed twice in PBS. Non-specific bind-
ing of the primary antibodies was blocked by incubating
the sections with "diluted normal serum" (10 ml PBS
containing 150 μl horse serum; Vector Laboratories,CA) for 20 minutes at room temperature. Slides were
then incubated with the primary antibodies at room
temperature for 60 minutes. After washing with PBS,
slides were incubated with the secondary antibody for
30 minutes and afterwards washed with PBS twice fol-
lowed by incubation with ABC-complex for another
30 minutes. Visualization was conducted using sub-
strate and chromagen 3,3'-diaminobenzidine (DAB;
Dako, Glostrup, Denmark) for 8–10 min. Slides were
then counterstained with Mayer's acidic hematoxylin
and dehydrated in ascending concentrations of ethanol
(50–98%). After xylol treatment, slides were covered.
MaCa 2402/02 served as a positive control for the
MUC1 staining. For negative controls, the primary anti-
body was replaced with normal control serum IgG. Posi-
tive staining resulted in a brownish color, negative
controls and unstained cells displayed a blue color.
VU3C6
Paraffin-fixed tissue sections were dewaxed with xylol
for 20 minutes and placed into 100% ethanol. Block-
ing of the endogenous peroxidase was done by a
combination of hydrogen peroxide and methanol for
20 minutes. Next, slides were dehydrated in descend-
ing concentrations of ethanol and washed twice in
PBS. Non-specific binding of the primary antibodies
was blocked by incubating the sections with "diluted
normal serum" (10 ml PBS containing 150 μl horse
serum; Vector Laboratories, CA) for 20 minutes at
room temperature. The remaining steps were the
same as described for VU4H5.
See Figure 1 for staining results of controls for each
antibody.
Immunohistochemical analysis
Slides were evaluated and digitalized with a Zeiss photo-
microscope (Axiophot, Axiocam, Zeiss, Jena, Germany).
Immunohistochemical staining was assessed using a
semiquantitative score according to Remmele and Steger
[20], comprising optical staining intensity (graded as 0 =
no, 1 = weak, 2 = moderate, and 3 = strong staining)
and the percentage of positively stained cells (0 = no,
1 = <10%, 2 = 10–50%, 3 = 51–80% and 4 = >80% cells).
The values for staining intensity and the percentage of
positively stained cells are multiplied, so a maximum
score of 12 can be reached. According to Remmele and
Steger, a score equal or less than 3 represents week
staining and a score above 3 moderate or strong stain-
ing. We defined cases with an IRS of equal or less than
3 as negative and cases with an IRS of 4 or higher as
positive which is consistent with previously published
studies [21]. Slides were reviewed by two independent
observers, including a gynecological pathologist (D.M.).
One slide per case was evaluated by a magnification of
Figure 1 Controls for VU4H5 and VU3C6. A, posive and B, negative control for VU4H5. C, positive and D, negative control for VU3C6. Breast
cancer tissue.
Table 2 Median and range for CA27.29 and CA 15–3
within different the histological subtypes
CA27.29 Serous (n=28) Mucinous (n=1) Endometrioid (n=15)
median 27.835 12.26 43.31
min 6.21 - 21.99
max 329.31 - 55.5
CA15.3 serous mucinous endometrioid
median 34.1 11.7 59
min 8.37 - 32.5
max 1240 - 65.3
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observers differed. These cases were jointly re-evaluated
by the observers. After re-evaluation both observers
came to the same result. The concordance before the re-
evaluation was 145 (92.95%).
Statistical analysis
Statistical analysis was performed by using SPSS 18.0
(PASW Statistic, SPSS Inc., IBM, Chicago, IL). Correl-
ation analysis of MUC1 expression was performed for
the histological subtype, tumour stage, grade and clinical
data with the non-parametric Kruskal-Wallis rank-sum
test and the non-parametric Spearman correlation coef-
ficient. Kaplan-Meier curves were drawn for the com-
parison of survival times. Differences between survival
curves were calculated using the chi-square statistic of
the log-rank test to test curves for significance. Signifi-
cance was assumed at p <0.05.
Results
CA 15–3 and CA 27.29 serum concentrations
Patients with benign ovarian disease (n=74) were further
classified into 32 patients with retention cysts (including
follicular cysts, corpus luteum cysts, endometriosis cysts,
serous cysts), 38 patients with benign tumours (serous
and mucinous cystadenoma, serous and mucinous cysta-
denofibroma, Brenner’s tumour, teratoma and fibroma)and four patients whose benign disease was not
specified.
Those patients with ovarian carcinoma (n=44) were
divided into serous (n=28), endometroid (n=15) and mu-
cinous (n=1) histology.
The median concentration of CA 15–3 was signifi-
cantly higher in patients with malignant disease (46 U/
ml; range: 8.37-2990 U/ml) than in patients with benign
disease (21 U/ml; range: 5.38-67.2 U/ml)(p<0.001).
Table 2 shows median, minimum and maximum con-
centrations measured for each histological subtype.
Evaluation of CA 27.29 also showed a significant
difference with median concentrations of 16 U/ml
(range: 4.00-48.77 U/ml) in patients with benign disease
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ovarian carcinoma (p<0.001).MUC1 expression in ovarian carcinoma tissue
Immunohistochemical analysis resulted in 37 positive of
152 evaluable cases for VU3C6 and 106 positive of 150
evaluable cases for VU4H5. Of the 37 samples positive
for VU3C6, 31 were positive for VU4H5, 4 were negative
and 2 samples were technically not evaluable for
VU4H5. The majority of positive samples (34) were of
serous histology. All cases of clear cell and mucinous
histology were negative for VU3C6 and only two cases
of endometroid histology were positive for VU3C6.
The distribution of positive cases for VU4H5 regarding
histological subtype was as follows: serous 82/107, clear
cell 7/10, endometroid 13/21 and mucinous 4/12.
Median overall survival for all patients was 3.3 years
(range 2.12-4.48). Figure 2 shows the expression of
MUC1 in ovarian carcinoma subtypes in boxplots. There
were significant differences in MUC1 expression be-
tween serous, clear cell, endometrioid or mucinous
forms of ovarian carcinoma.
The correlation of the staining results for both anti-
bodies with tumour grade, FIGO stage and pT-stage
revealed results of varying significance: With respect to
tumour grade we found a positive relationship between
the tumour feature and MUC1 when samples were eva-
luated for VU4H5 (p=0.003), see Figure 3, but not for
VU3C6 (p=0.104). The same positive relationship was
found for VU4H5 regarding FIGO stage (p=0.047), but
not for VU3C6 (p=0.115). A positive relationship for
both antibodies was found when expression was corre-
lated with pT stage (VU4H5: p=0.010; VU3C6: p=0.031),
see Table 3.Figure 2 MUC1 Expression within the different histological subtypes.
(A, p=0.008) and VU3C6 (B, p<0.001). The boxes represent the range betwe
The bars delineate the 5th and 95th percentiles.Prognostic value of MUC1 expression
Overall survival was correlated with the expression of
VU3C6 and VU4H5. VU4H5 turned out to be a negative
prognosticator in ovarian carcinoma patients. Patients
with a negative VU4H5 expression showed significantly
better mean overall survival (9.33 years; range: 7.09-
11.57 years) when compared to patients with positive ex-
pression (6.27 years; range: 4.90-7.64 years), p=0.011.
This applied to the serous subtype in particular. Mean
overall survival for patients with serous MUC1 positive
ovarian carcinoma was 4.98 years (range: 3.82-6.13)
compared to 8.77 years (range: 5.69-11.85) for patients
with negative expression, evaluated by VU4H5
(p=0.032). However in multivariate Cox-Regression ana-
lysis VU4H5 did not prove to be an independent prog-
nostic marker in ovarian carcinoma cases. The
expression of VU3C6 was not related to patients’ out-
come, neither in the whole cohort (p=0.262) nor in the
serous subgroup (p=0.257). See Figure 4 for survival
curves of all patients and Figure 5 for survival curves of
the subgroup of serous ovarian carcinoma patients.Discussion
The first part of this study evaluated serum concentra-
tions of CA 15–3 and CA 27.29 measured in sera of
patients with either benign or malignant tumours of the
ovary. One aim of this study was to compare CA 15–3
and CA 27.29 in benign and malignant ovarian disease.
Median concentrations showed significant differences
between benign and malignant disease, but with high
variability of the absolute value, so differentiation of be-
nign and malignant disease by CA 15–3 or CA 27.29
does not seem possible. According to our results neither
CA 15–3 nor CA 27.29 will have the potential to serveSignificant differences of expression were found for VU4H5
en the 25th and 75th percentiles with a horizontal line at the median.
Figure 3 Expression of MUC1 in ovarian carcinoma shown by grading. A, Significant differences of expression were found for the VU4H5
epitope (p=0,003). B, week staining (IRS=2) for VU4H5 in a grade 1 carcinoma. C and D, strong staining (IRS=8) in cases with grading 2 and 3,
respectively.
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Besides, the sample is not large enough to evaluate these
markers for different histological subtypes of ovarian
carcinomas since the number of cases of each histo-
logical subtype is very small.
In order to evaluate the potential of CA 15–3 to aid
early detection of ovarian cancer, Shutter et al. investi-
gated the combination of CA 15–3, CA 125, and CA
72–4 [22], but CA 15–3 was not able to improve the sig-
nificance of this test. Other studies showed that MUC1
measured in sera of patients with platinum resistant dis-
ease inversely correlates with overall survival and might
thus be useful as a prognostic marker [23,24]. However,
MUC1 might be able to add diagnostic significance in
addition to CA 125 testing which needs to be investi-
gated in future studies.
The second part of this study evaluated MUC1 ex-
pression by IHC where two epitopes were targeted.Table 3 VU4H5 and VU3C6 were correlated to the extent of t
correlation is significant at the ** 0.01 level (2-tailed), * 0.05
VU
Spearman's rho VU4H5 Correlation Coefficient 1.
Sig. (2-tailed)
VU3C6 Correlation Coefficient 0.
Sig. (2-tailed) < 0.VU4H5 is one of the most commonly used antibodies
when targeting MUC1 and previous studies have
shown a positive correlation for lymph node involve-
ment and a higher staining intensity for higher grade
breast cancer lesions [25]. Studies that evaluated the
prognostic role of MUC1 in ovarian cancer also found
a significant association with clinical-pathological fea-
tures such as tumour stage, grade, residual disease sta-
tus and presence of ascites [26]. Only the aberrantly
glycosylated MUC1 is found to be over-expressed in
ovarian cancer, whereas normal ovarian surface epithe-
lium and serous cystadenomas do not express these
epitopes [27]. Our results underline the possible prog-
nostic potential of MUC1 in regard to tumour grade,
FIGO stage and survival. Interestingly, this is only
true when targeting the VU4H5 epitope as VU3C6
did not show significant differences for the mentioned
variables.he primary tumour (pT), grade and FIGO stage;
level (2-tailed) and significant results are shown in bold
4H5 VU3C6 pT grade stage
000 0.4860 0.209 0.24 0.162
< 0.001** 0.010* 0.003* 0.047*
486 1.000 0.174 0.131 0.127
001** 0.031* 0.104 0.115
Figure 4 Overall survival for all patients of our study cohort. Kaplan-Meyer curves showing overall survival. Results for VU4H5 showed
significant differences (p= 0.011, A), but VU3C6 did not (p=0.262, B).
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ker in breast cancer and early studies suggest it may be a
useful target for vaccine strategies [20]. MUC1 as a tar-
get for immunotherapy has, however, encountered chal-
lenges. It is expressed on normal cells and so far we do
not have the ability to distinguish between tumour-
associated MUC1 and normal MUC1; the shed N-
terminal subunit acting as a large pool to absorb the
antibody [28]. However, in vitro studies on ovarian can-
cer cell lines were able to show increased sensitivity to
docetaxel when combined with the monoclonal antibody
MAb C595 and in vivo studies using a MUC1/docetaxel
conjugate showed higher cytotoxicity than docetaxel
alone in multidrug resistant ovarian cancer [29,30]. Ano-
ther study compared patients that were treated with aFigure 5 Overall survival for the subgroup of serous ovarian carcinom
VU4H5 showed significant differences (p= 0.032, A), but VU3C6 did not (p=Yttrium-labeled monoclonal antibody recognising an
extracellular portion of MUC1 versus controls treated by
standard therapy alone. In this study no significant dif-
ference in terms of time to relapse and overall survival
was found [31]. Our study shows a worse outcome for
patients with high expression of MUC1 in ovarian car-
cinoma and thus supports its potential for targeted the-
rapy. Future clinical studies will have to find out the
most efficient conjugate.
Conclusions
In this study, the median expression of MUC1 was sig-
nificantly different in the serum of patients with benign
and malignant ovarian disease, but the variability of the
absolute value in patient’s sera is high so that a cleara patients. Kaplan-Meyer curves showing overall survival. Results for
0.257, B).
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not possible. Our results from IHC indicate a prognostic
relevance of MUC1 in ovarian carcinoma when eva-
luated by the VU4H5 antibody. New therapeutic stra-
tegies may also directly target MUC1 and increase efficacy
and specificity of anticancer treatment. However, our
study has some limitations since we investigated only two
out of a variety of existing anti-MUC1-antibodies. Ovarian
cancer is a heterogeneous disease. Our study cohort con-
sists of different numbers of serous, endometroid, clear
cell and mucinous ovarian carcinoma cases. Future studies
need to investigate other existing antibodies in regard to
their specificity and sensitivity of detecting MUC1 epi-
topes and should focus on differences regarding each
tumour type.
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